Chronic kidney disease (CKD) has been related to allogeneic haematopoietic cell transplantation (HCT) as a late effect caused by a variety of factors. We retrospectively evaluated the development of CKD in 230 patients, aged 34 (5-65) years, who had undergone allogeneic HCT for haematological disease, using sibling or unrelated donors and myeloablative or reduced conditioning regimens. Pre-HCT glomerular filtration rate (GFR) was within normal limits (108 ± 28 mL/min/1.73 m 2 ) in patients who did not develop CKD and 95 ± 24 mL/min/1.73 m 2 in those with CKD postHCT, while the GFR 12 months post transplant declined to 104 ± 26 and 69±19 mL/min/1.73 m 2 , respectively. CKD incidence was 20.4%, with a median time of development of 6 (3-18) months post transplant. On multivariate analysis, risk factors for CKD were the presence of chronic GVHD (cGVHD; P ¼ 0.001), unrelated donor transplantation (P ¼ 0.008), post-transplant event of acute kidney injury (AKI) (P ¼ 0.002) and older age (P ¼ 0.002). In long-term survivors stable significant predictors for CKD were older age at transplantation, cGVHD and AKI. CKD did not influence non-relapse mortality. In our study, cGVHD emerges as an important cause of kidney injury in HCT survivors, regardless of administration of nephrotoxic agents.
INTRODUCTION
Allogeneic haematopoietic cell transplantation (HCT) is a widely accepted and administered approach for malignant and nonmalignant haematological diseases, offering the potential of cure in affected patients. Currently, B55 000-60 000 HCTs are performed worldwide every year, as advances in alternative-donor transplantation have widened the availability of HCT. 1 Patients with pre-existing comorbidities, those heavily pretreated with extensive chemotherapy or irradiation are at particularly high risk for developing serious, sometimes fatal complications. These complications can occur early after HCT (within 100 days) or late after HCT. 2 Currently, the goal of its use is not only its curative potential but also the minimization of severe complications or organ damage and the preservation of good quality of life in longterm survivors. Over the last 40 years there has been a significant improvement in supportive care and even sophisticated alternative transplant strategies have been translated to a better outcome. Despite the progress, it is well known that vital organs may be affected by the procedure and subsequent morbidity emerges. The cumulative incidence of a chronic health condition among HCT survivors is 59% at 10 years. As reported by Tichelli et al. 2 nonmalignant complications, early, late or very late, are heterogeneous in nature and severity; they affect mainly lungs, heart and kidney.
Chronic kidney disease (CKD) is a frequent complication after HCT. In most cases of CKD, an entity multifactorial in nature, the cause used to be considered idiopathic. The former was named after different terms, such as 'BMT nephropathy', 'radiation nephritis', 'conditioning-associated HUS'. Nevertheless, new concepts regarding the pathophysiology of CKD in long-term HCT survivors have emerged, leading to the recognition of additional risk factors for CKD development. In the current study, we investigated factors associated with kidney injury following HCT, such as nephrotoxic medications, chemoradiotherapy of myeloablative or reduced intensity conditioning, major post-transplantrelated complications, severe infection and presence of GVHD.
PATIENTS AND METHODS

Study population
We analyzed the clinical data of 230 patients (130 males and 100 females) with a median age of 34 (5-65) years, who underwent consecutively allogeneic HCT at our institution between 2001 and 2010. Patient demographic, clinical and laboratory data were collected by reviewing medical records following patients' informed consent.
The study cohort consists of all transplanted patients who eventually had pretransplant GFR460 mL/min/1.73 m 2 and survived to at least þ 3 months. They had sufficient long-term serum creatinine data (defined as having at least 2 GFR data after day þ 120). The majority of the study population were adults (n ¼ 199 adults, n ¼ 31 children). Adults and children were defined using the threshold of 18 years at the HCT day. Underlying diseases are presented in Table 1 . Most patients received grafts from an HLA-identical sibling (n ¼ 170, 73.9%), whereas the minority received grafts from unrelated donors (n ¼ 60, 26.1%). The majority of unrelated donors were HLA-A,B,C,DRB1 (8/8) matched while 15 out of 60 donors were 7/8 Ag matched. G-CSF-mobilized PBSC and BM cells served as the graft source for 190 patients (82.6%) and 39 patients (17%), respectively. No ex vivo graft manipulation was performed.
was reviewed in detail for abnormal laboratory values and clinical evidence of complications. The complications recorded and analyzed are illustrated on Tables 3 and 4 . HCT procedures regarding the conditioning regimen, GVHD prophylaxis and treatment are provided as Supplementary data.
Definition of acute kidney injury (AKI)
AKI was defined as an abrupt (within 48 h) decline of kidney function as confirmed either by an increase in serum creatinine of X0.3 mg/dl (26.4 mmol/l) and of X50% (1.5-fold from baseline), or by documented oliguria (40.5 mL/kg/h for more than 6 h). 3 
Definition of CKD
In the present study, CKD was defined as a GFRo60 mL/min/1.73 m 2 (estimated by the modification of diet in renal disease (MDRD) formula and the Schwartz formula for children) being persistent for more than 3 months post transplant or longer than 6 months whenever the patients were on calcineurin inhibitor treatment.
Statistical analysis
Continuous variables are displayed as the median, with ranges in parentheses. For dichotomous variables, the frequency of occurrence is given along with the corresponding percentage. Continuous data were compared using a t-test or the Mann-Whitney test for non-normally distributed unpaired variables, while categoric variables were compared using a w 2 -test, and, where appropriate, Fisher's exact test. The potential predictive factors for occurrence of CKD identified on univariate analysis at a significance level of Pp0.1 were included in the multiple logistic regression model. The statistical significance of the variables in the model was tested using the Waid test at a 5% significance level. For the associated odds ratios (OR), 95% confidence intervals were computed. All statistical tests were two-sided, with Pp0.05 indicating statistical significance. Survival was analyzed by the Kaplan-Meier method and survival curves between groups were compared using a long-rank test. All statistical analysis was performed using SPSS version 16 (SPSS Inc., Chicago, IL, USA).
RESULTS
CKD occurrence
At the latest assessment and at a median follow-up of 21 months (range 6-118 months), 113 patients were alive from a total of 230 evaluated patients. Cause of death was relapse of primary disease in 67 patients, transplant-related complication in 47 patients and other reasons in 4 patients. The probability of OS was 41% at 10 years for the whole cohort, whereas no difference in survival was encountered between nonrelapsed patients with and without CKD (Figure 1 ).
CKD occurred in 47 out of 230 patients (20.4%) at a median time of 6 months (range 3-18 months). Among patients with CKD, 29/ 170 patients received grafts from siblings and 18/60 patients from unrelated donors. The majority of our population who developed CKD (29 out of 37) had stage 3 CKD, four patients out of 37 developed stage 4 CKD, and three had end-stage CKD. Furthermore, chronic GVHD (cGVHD) presented in the kidney as nephrotic syndrome in five patients. Renal biopsies revealed minimal change nephropathy in three patients and membranous nephropathy in the other two.
The mean GFR declined over the study period but remained at or above the 60 mL/min/1.73 m 2 . Patients older than 40 (n ¼ 81) and patients younger than 40 years (n ¼ 149,) developed CKD in 30.9% vs 14.5% respectively (P ¼ 0.003) ( Table 2 ). Patients with GFR o90 mL/min/1.73 m 2 before HCT (n ¼ 71) progressed to CKD in 29.6% of cases, while only five of the 57 patients with GFR 4120 mL/min/1.73 m 2 (8.8%) developed CKD (P ¼ 0.015). For the whole cohort, mean GFR at 3, 9, 12 months after HCT (91 ± 35 , 96 ± 31 and 95 ± 29 mL/min/1.73 m 2 , respectively) significantly declined from the mean baseline GFR (108 ± 28 mL/min/ 1.73 m 2 ) (Po0.001).
Univariate analysis of risk factors for CKD Significant pretransplant risk factors for CKD were older age (P ¼ 0.002), type of transplantation (P ¼ 0.028) and below normal GFR 1 month before HCT (P ¼ 0.003) ( Table 3) . Table 4 summarizes the univariate analysis of post-transplant factors related to CKD. Post-transplant factors significantly associated with CKD development, as illustrated on the univariate analysis, were: occurrence of cGVHD (Po0.001), CMV reactivation (P ¼ 0.03), treatment for fungal infection (P ¼ 0.01), history of AKI (Po0.001) and the number of AKI 
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Severe aplastic anaemia 9 (3.9) GVHD-associated CKD after allo-HCT I Sakellari et al events that had occurred before the establishment of CKD (Po0.001). Primary disease, gender, TBI administration, type of conditioning regimen, occurrence of aGVHD, veno-occlusive disease and hemorrhagic cystitis were not identified as risk factors. There was a trend of antithymocyte globulin (ATG) treatment (P ¼ 0.08) or post-transplant thrombotic thrombocytopenic purpura occurrence (P ¼ 0.07) towards CKD development but it did not reach statistical significance.
Multivariate analysis of risk factors for CKD All the significant factors in the univariate analysis were selected for consideration in the multivariate model. Tables 3 and 4 summarize the independent predictors of developing CKD, determined by multivariate analysis using forward stepwise regression: age at transplantation (P ¼ 0.002, OR: 1.04, 95% CI: 1.008-1.072), type of transplantation (sibling vs unrelated) (P ¼ 0.008, OR: 3.4, 95% CI: 1.4-8.4), cGVHD (P ¼ 0.001, OR: 10.4, 95% CI: 2.8-8.9), occurrence of AKI (P ¼ 0.002, OR: 4.2, 95% CI: 1.7-10.7).
Analysis of risk factors for CKD in subcategories CKD according to age. In the pediatric population (n ¼ 31, 13.5% of the cohort) risk of CKD was 6.5%. In contrast, when the analysis was restricted to adult patients (18-65 years old, n ¼ 199) an increased risk of CKD (n ¼ 45, 22.6%) was illustrated. On multivariate analysis of the adult patient group cGVHD (Po0.001, OR: 16.3, 95% CI: 3.5-81) and AKI (P ¼ 0.001, OR: 5.1, 95% CI: 2.1-15.1) remained independent prognostic factors for CKD. In the univariate analysis type of transplantation (P ¼ 0.008), GFR before transplantation (P ¼ 0.006), age at transplantation (P ¼ 0.016), AKI (Po0.001) and the number of preceded events of AKI were associated with development of CKD. Multivariate analysis revealed the AKI occurrence to be the only independent prognostic factor for CKD in this subgroup (P ¼ 0.001, OR: 2.1, 95% CI: 1.3-3.3).
CKD according to long-term survival. Restricting the analysis in the group of patients that survived longer than a year (n ¼ 152, 66.1% of the initial study population), we observed that 35 patients (23%) experienced CKD. Unrelated transplantation (P ¼ 0.008), ATG treatment (P ¼ 0.052), presence of cGVHD (P ¼ 0.011), treatment for fungal infection (P ¼ 0.014), history of AKI (Po0.001), the number of preceded events of AKI (P ¼ 0.001), age at transplantation (P ¼ 0.021) and GFR value before transplantation (P ¼ 0.012) were found to be significantly associated with the development of CKD in univariate analysis. Patient age at transplantation, development of cGVHD (P ¼ 0.012, OR: 5.1, 95% CI: 1.1-23.8) and occurrence of AKI (P ¼ 0.009, OR: 4.4, 95% CI: 1.5-12.6) after HCT were the only independent predictive factors for CKD, as revealed by the multivariate analysis in the long-term survivors group.
The multivariable logistic regression model that was developed using all patients of the study cohort (n ¼ 230) and for each of the subcategories (aged above 18, AKI, cGVHD and long-term Abbreviations: AKI ¼ acute kidney injury; CKD ¼ chronic kidney disease; cGVHD ¼ chronic GVHD; TTP ¼ thrombotic thrombocytopenic purpura.
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DISCUSSION
HCT has been established as an indicated therapeutic strategy for thousands of patients worldwide annually. The downsides to allogeneic transplantation are mainly toxicity-related, due to the conditioning regimen itself, the immunosuppression and the development of GVHD. In this context, we retrospectively studied CKD, which has been reported to occur post HCT at markedly higher rates than those of 4.3% and 0.2% for moderate and severe CKD, respectively, which are the rates observed in the general population. Specifically, in retrospective cohort analyses postHCT, the corresponding rates have been reported to be 12-29% and 3-3.6%, respectively. 4 In our study, the incidence of CKD was 20.4% at a median of 6 months (range 3-18 months) in the whole cohort of our transplanted population, whereas it varied among different subcategories.
In various studies, CKD has been associated with older age, lower pretreatment GFR, TBI, the use of fludarabine in the conditioning regimen, amphotericin B treatment, female gender, GVHD, the use of calcineurin inhibitors, and a variety of other variables. 5, 6 Although early studies focused on the toxicity of the conditioning or the concurrent toxic medication, they did not reveal any clues to organ damage.
We comprehensively evaluated the factors contributing to CKD post allo-HCT. Our study showed that older age, unrelated transplantation, preceded event of AKI and cGVHD were independent risk factors for chronic kidney injury after HCT. Kersting et al. 7 reported that CKD after myeloablative HCT was found with a cumulative incidence of 20% after 5 years and pretransplant risk factors for CKD were: lower than normal GFR at HCT, female sex and older age. Of patients with suboptimal kidney function before HCT, more than half progress to CKD.
In the current study, risk of CKD seemed to be similar in transplantation post reduced-intensity and myeloablative conditioning, being in agreement with the findings of other studies. 8 However, it was higher in unrelated transplant recipients as compared with sibling graft recipients. Among other factors, transplant from an unrelated donor has been identified as major adverse predictor for CKD development post HCT. The increased alloreactivity and consequently the increased rates of GVHD (both acute and chronic) are the main explanations of the above finding, which is focused on the hypothesis and the fact of GVHD-related CKD. The alloreactive donor T cells, which recognize the host minor and MHC Ags, proliferate and damage target tissues. The complications post HCT illustrate the great diversity in respect of incidence, time of appearance, risk factors and outcome.
The administration of ATG, which was given consecutively to unrelated transplants, was shown to have a trend for significance in univariate analysis of the whole patient group and reached statistical significance in the multivariate analysis in the subgroup of patients with a history of AKI. The above finding might be ascribed to the use of ATG in the unrelated setting.
CKD developed partly as a consequence of AKI, which is a common complication in HCT patients usually occuring within the first 100 days. [8] [9] [10] [11] [12] Both myeloablative and non-myeloablative regimens have been associated with AKI, although its severity has been reported to be higher in the myeloablative HCT setting. 13 Myeloablative conditioning, hepatic VOD, 14 cis-platinum II nephrotoxicity, 15 acute GVHD, 16 amphotericin administration, admission to intensive care unit, 14 CMV reactivation, 16 diabetes melitus and elevated baseline GFR 17 have been described as risk factors for AKI in both myeloablative and reduced intensity HCT. In our study, 30.2% of patients with AKI developed CKD at 6.5 months post-transplant, ranging from 3 to 18 months. In addition, in this subgroup, cGVHD (P ¼ 0.001, OR: 41.5, 95% CI: 4.6-353. 7) and ATG (P ¼ 0.004, OR: 0.2, 95% CI: 0.1-0.6) were the only independent prognostic factors for CKD, revealing their main role in an immune-mediated process that leads to kidney injury.
GVHD, acute or chronic, seems to account for the manifestation of renal involvement either as a direct target of T cell-mediated organ damage or as an indirect effect of cytokine-mediated nephropathy. 18, 19 The increased use of mobilized peripheral blood as a stem cell source may be associated with a higher risk of cGVHD and in our case the majority of our patients received mobilized peripheral blood (82.6%) stem cells.
The course of cGVHD is highly variable; many patients have eventual resolution of cGVHD and are able to discontinue all immunosuppressive treatment as tolerance is mutual, while others have severe and treatment-refractory manifestations for a longterm period. Several variables related to GVHD treatment were investigated, that is, duration and lines of treatment of cGVHD, need for triple therapy. However, the most outstanding variable was the presence of cGVHD, even in subcategories of the population and long-term survivors. Our results are in line with recent data from other studies. [18] [19] [20] The pathogenetic mechanism of GVHD-associated CKD that was proposed by the National Cancer Institute consortium, 21 involving not only CKD but also other late complications and end-organ damage postHCT, is endothelial injury-related. Injury of the endothelium, the principal target tissue of cGVHD, may initially lead to inflammation, cytokine cascade through tumor necrosis factor-a (TNF-a), IL-6 and transforming growth factor-b (TGFb) and later to fibrosis and organ failure as a result of the immune intolerance of cGVHD. [22] [23] [24] [25] [26] [27] [28] In the case of CKD, enhanced alloimmunity and cellular cytokine storm due to GVHD may promote renal fibrogenesis, which is generated by a tissue environment invaded by inflammatory cells.
The underlying origin of CKD is reported to be multifactorial. Much of the excess HCT-related morbidity among CKD patients relates to the toxic effects of the conditioning regimen, despite the fact that no association with the use of TBI or fludarabine in the conditioning regimen was found in our study. TBI may induce sclerosis of the arteries and capillaries, interstitial fibrosis and may have an important role in renal damage. [29] [30] [31] [32] In our study, TBI was not an etiological pathogenetic factor in contrast to other studies showing dose-dependent toxicity, even in children. 18, 20, 30, [32] [33] [34] [35] Calcineurin inhibitors used for GVHD prophylaxis and treatment have been mainly associated with various degrees of nephrotoxicity in the majority of previous studies. 8, 19, 32, 36 In the present study, calcineurin inhibitors as nephrotoxic agents were not evaluated per se, due to the universal administration. However, their toxicity of long-term use and the number of lines of anti-GVHD treatment were examined and found to have an insignificant impact on CKD development. An explanation may be the variability in CYA trough levels within a patient and the transient effect of CYA on renal function. However, this is only true if CYA is adequately monitored and dose adjustments are made depending on CYA trough levels and/or rise in creatinine, as we did in our center. Despite the absence of CYA in T-cell-depleted HCT in a study published in 2010 by Glezerman et al., 37 CKD developed after exposure to TBI in older age and post-thrombotic microangiopathy.
In line with previous studies, we also demonstrated that among patients with suboptimal kidney function before HCT, one-third progressed to CKD. 7, 12, 38 In addition, we observed that older age, which is a risk factor in the general population, was proven a significant predictive factor for the development of CKD. Female and older patients are more susceptible to decline in kidney function. 7, 8, 33, 36, 39, 40 End-stage renal disease requiring chronic dialysis treatment or kidney transplant developed in three CKD (stage 5) patients at a median of 5 (3-9) years postHCT. One of the patients is a young man who had undergone unrelated donor HCT for severe aplastic anemia in our center. He developed CKD and started dialysis treatment 2 years later. Eventually, kidney transplantation was performed, his mother being the donor. He is alive and well 5 years post solid organ transplantation and 10 years post HCT. In an EBMT study, 15 renal solid organ transplantations were performed after HCT with 100% OS at 5 years, in a period covering HCT between 1984 and 2007. 41 These reports reflect the growing number of patients with CKD that need to be treated with solid organ transplantation.
Our study has several limitations. First, an obvious limitation is its retrospective nature that describes the experience of a single BMT center. Until sensitive and robust biomarkers to evaluate and diagnose kidney injury are to be introduced, our experience has to be evaluated, expanded and shared. Furthermore, it would be more precise to report the rate of microalbuminuria and/or uncontrolled hypertension in our sample. It is well known that microalbuminuria is considered a marker of endothelial dysfunstion, associated with a faster rate of GFR decline. 42, 43 In our study, overt proteinuria 4300 mg/g and the occurrence of nephrotic syndrome was recorded and further evaluated. However, the retrospective nature of our study did not allow us to evaluate the rate of microalbuminuria, which causes CKD in a long-term period. On the other hand, CKD caused by hypertension may be developed after one or two decades of uncontrolled hypertension. 43 Thus, hypertension was not included in our analysis, as it was well controlled in all subjects.
In conclusion, even in terms of CKD, cGVHD exemplifies the double-edged sword of alloreactivity. However, the possible benefit from transplant, in terms of reduced risk of relapse, should ideally outweigh organ toxicity. cGVHD is the most significant determinant of post-transplant quality of life, in addition to its role as a major cause of long-term morbidity and mortality in survivors of HCT. HCT has become a life saver for thousands of patients throughout the world. The widespread application of HCT is based on the patient's hope for surviving a fatal disease and the challenge emerges when we try to offer to them similar survival chances to those of the general population.
